six months after study group assignment. They assessed PD, the distance from the cementoenamel junction to the gingival margin (CEJ-GM) and bleeding on probing (BOP) at six sites on all teeth except third molars. They computed clinical attachment level (CAL) for each site from the PD and CEJ-GM measurements. They scored dental plaque at each tooth site as detectable (1) or undetectable (0, with a probe or visually) and computed it as a full-mouth percentage.
Outcome assessment. We assessed change in clinical periodontal status by using three outcomes: six-month change from baseline in full-mouth mean PD, fullmouth mean CAL and the percentage of tooth sites with BOP. Our study included data from 473 participants (240 treatment group participants and 233 control participants) of the 514 participants for whom complete baseline and six-month periodontal data were available.
Statistical analysis. We used individual analysis of variance or Pearson product moment correlations initially to explore bivariate associations between change in full-mouth mean PD, CAL and BOP and the following baseline factors: baseline disease severity (quartile split), treatment group (immediate treatment or delayed treatment [control] ), age (in years), sex, race (African American, white or other), ethnicity (Hispanic or nonHispanic), smoking history (current, former, or never), HbA 1c level (percentage), duration of diabetes (self-reported, in years), body mass index ([BMI] in kilograms per square meter, ≤ 30 versus > 30), full-mouth average clinical measurements, dental plaque, diastolic blood pressure (in millimeters of mercury), self-reported overall health and brushing and flossing frequency, and clinical site.
We constructed multiple regression models to evaluate associations between changes in periodontal measurements with various baseline factors simultaneously. We considered factors with P values < 0.1 in bivariate associations with the outcome of interest (change in PD, CAL or BOP) for inclusion in the regression models. We also evaluated all two-way interactions between these factors. We used backward selection to determine the final model. We removed nonsignificant interactions and factors (P > .05), and the final models included only factors significantly associated with the outcome. We selected factors by using an F test based on a type 3 sum of squares. We reported both unadjusted P values and P values with Bonferroni adjustment for multiple tests.
The clinical enrollment site was statistically significant in each model. Because our goal was to explore predictors useful to a clinician, in this article we do not report the clinical site effect, although it was adjusted in all models. Although the primary analysis included all trial participants and included "treatment" in the model, we also studied associations in the treatment group alone and developed multivariate models as described previously. For these analyses, we grouped change in PD, CAL and BOP according to tertiles, and we explored the relationship between baseline characteristics and change (categorized by tertile) by using generalized logistic regression. Results from the two sets of analyses were qualitatively similar, and in this article we report only results regarding the mean change in each clinical measurement that include all participants. In addition to calculating mean full-mouth PD, CAL and BOP changes, we also computed changes in these clinical measures stratified according to baseline disease severity to compare the clinical response among DPTT participants with summaries of patients' clinical responses typically reported in the literature. To determine this, we averaged changes at sites with baseline probing depths of 3 mm or less, 4 to 6 mm, and 7 mm or more within, then across, participants. For each participant, we used only changes at qualifying sites to calculate mean change. We used linear mixed-effect models, which accounted for intraparticipant correlations, to compute group means, standard deviations (SDs), and P values used to compare treatment groups. We performed all data analyses by using statistical software (SAS 9.3, SAS Institute, Cary, N.C.). Table 1 summarizes baseline characteristics in the treatment and control groups. The majority of participants were white and non-Hispanic. Although not shown in the table, overall, the most prevalent self-reported ethnic groups according to race (data not shown) were non-Hispanic white (n = 154), non-Hispanic black (n = 135), Hispanic white (n = 105) and Hispanic Native American (n = 35). Only one participant reported being Hispanic and black. Sixty-one of 473 participants (12.9 percent) were current smokers. Participants had relatively long-standing diabetes (mean duration, > 10 years) and more than 70 percent were obese (BMI > 30 kg/m 2 ). Participants had widespread periodontitis, although relatively few sites per participant had advanced PD and CAL (that is, ≥ 7 mm for both PD and CAL). Table 2 presents the mean changes in PD, CAL and BOP according to treatment group and baseline PD severity. The treatment group experienced significantly greater changes in these measures than did the control group. Full-mouth mean changes in control participants were small and clinically insignificant. Within the treatment group, mean PD reduction ranged from 0.16 mm in sites with baseline PDs of 3 mm or lower to 1.92 mm in sites with baseline PDs of 7 mm or greater. In untreated control participants, mean PD increased (that is, deepened) slightly in initially shallow sites and improved in initially deep sites. Changes in CAL after treatment followed the same pattern as noted for PD. In contrast, the magnitude of change in BOP was similar across the baseline PD categories-about 20 percent. Findings of the linear trend test, which gauged whether the change in each clinical measure steadily increased (or decreased) across categories, were significant (P < .01) for PD and CAL but not for BOP.
RESULTS

Periodontal treatment response.
Variables associated with change in PD, CAL and BOP. Tables 3 through 5 (pages 1232-1236) summarize the results of the multivariate analyses. For each outcome, we first present the main effects between periodontal change and each factor and then summarize the significant two-way interactions. Hispanic ethnicity was not significantly associated with change in any measure, but we retained it in the models for PD and CAL change because of the significant treatment-according-to-ethnicity interaction for these outcomes (see below). In bivariate analyses, baseline plaque was associated significantly with change in each periodontal measure (P < .0001), but we excluded it from the final models because of its collinear relationships with the baseline disease severity measures (P < .0001 for all correlations between baseline plaque and baseline disease measures). For PD change, treatment group, BMI and baseline PD remained significant in the multivariate model (Table  3) . Participants in the treatment group, those with higher mean baseline PD, and those who were obese experienced greater mean PD reductions than did control group participants and those with lower initial PD and BMI values. When we controlled for all other factors in the model, participants who were obese experienced a 0.10-mm greater reduction in PD than did their counterparts who were not obese (P = .0007). Two interactions (Hispanic ethnicity according to treatment group and (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) , .0001 * Analyses were based on linear mixed-effect models to account for intraparticipant correlations. Six-month changes in periodontal measurements were included as dependent variables and the treatment group status as an independent factor. For each participant, only changes at qualifying sites were used to calculate full-mouth mean change. For example, for the category "Baseline PD ≥ 7 mm," only changes at sites initially 7 mm or greater in depth were included in calculating the mean change for that person. Thus, although a participant could have contributed sites to each of the categories, each tooth site was included in only one category. The number of qualifying sites per person, however, could vary by category. † Treatment effect: Difference in average change in periodontal measurements (six months -baseline) between the treatment groups (control group -treatment group). Negative values for change indicate improvements from baseline. Treatment effects and 95 percent confidence intervals (CIs) were determined from linear mixed-effect models and P values testing for treatment effects involved the use of t tests based on mixed-effect models. Changes were averaged within participants and then within groups. ‡ Number of participants having at least one site in the baseline PD severity category. § SD: Standard deviation. ¶ Mean (SD) numbers of sites with baseline PD of ≤ 3 mm were 100.75 (29.96) and 98.03 (32.13) for the treatment and control groups, respectively. # Mean (SD) numbers of sites with baseline PD of 4-6 mm were 47.25 (23.38) and 45.57 (23.82) for the treatment and control groups, respectively. ** Mean (SD) numbers of sites with baseline PD of ≥ 7 mm were 3.25 (6.03) and 3.52 (8.34) for the treatment and control groups, respectively. † † Data regarding bleeding on probing at six months were missing for one participant.
baseline PD according to treatment group) also remained significant in the model. PD changes were associated more strongly with baseline PD in the treatment group than in the control group (Table 3) . For example, mean PD reductions in the treatment group increased from 0.22 mm in those with a mean baseline PD of 2.84 mm or less to 0.83 mm in those with baseline PD greater than 3.59 mm. The respective values in the control group ranged from a 0.08-mm increase to a 0.20-mm reduction. Finally, the difference in PD change between test 
Main Effects
Study group
Not applicable (NA) and Hispanic ethnicity, and interaction between treatment and baseline PD as covariates. Age, race, baseline body mass index, diastolic blood pressure, self-reported overall health, gingival health and frequency of flossing also were evaluated but were removed from the final model because they were not associated significantly with six-month PD change. The plaque score was excluded from the final model because it was associated collinearly with baseline PD. ‡ CI: Confidence interval. § P value remained significant after Bonferroni adjustment (P < .05/20 = .0025). ¶ Superscript lowercase letters ( a, b, c, d, e, f ) denote differences in six-month periodontal changes between the treatment and control groups within each Hispanic ethnicity group (Yes/No) and within each baseline PD level (≤ 2.84, 2.84-3.15, 3.15-3.59 and > 3.59). The same letter is used to represent the difference in the six-month change in periodontal outcome between the treatment and control groups for each Hispanic ethnicity and baseline PD category.
and control groups was significantly greater in Hispanic participants than in non-Hispanic participants. To further explore the effect of ethnicity on PD change, we compared the mean change between non-Hispanic white participants (75 treatment and 79 control) and black participants (73 treatment and 62 control) and between Hispanic white participants (54 treatment and 51 control) and non-Hispanic white participants (75 treatment and 79 control) (data not shown). The mean (standard error of the mean) change did not differ between non-Hispanic white participants and black participants (0.07 [0.08] mm; P = .35) but was significantly greater in Hispanic white participants than in non-Hispanic white participants (0.38 [0.09] mm; P < .0001). For CAL change (Table 4) , treatment group, baseline CAL, and the treatment-group-according-to-baseline-CAL and treatment-group-according-to-Hispanicethnicity interactions remained significant in the model. Again, treatment group participants and those with higher baseline CAL values experienced greater improvements in CAL than did control group participants and those with lower initial mean CAL. As with PD change, the difference in CAL change between test and control groups was significantly greater in Hispanic participants than in non-Hispanic participants. The change in CAL increased monotonically with increasing baseline CAL in the treatment group but not the control group.
Treatment group, BMI and baseline BOP were associated significantly with change in BOP ( Table 5) . As with PD change, participants who were obese experienced a greater reduction in BOP than did participants who were not obese (adjusted mean difference = 7.6 percent; P < .0001).
Only one interaction, treatment group according to baseline BOP, remained significant. Within the treatment group, BOP decreased steadily with increasing baseline BOP, from 2.7 percent in those with the least extensive baseline BOP (< 39.9 percent) to 36.3 percent in those with the most extensive BOP (> 81.9 percent). Interestingly, baseline HbA 1c level, diabetes duration and smoking status were not associated significantly with treatment response. To further explore the effect of diabetes measures on periodontal response, we calculated Pearson product moment correlations between change in PD, CAL and BOP and baseline HbA 1c level and diabetes duration (in years). For both the combined groups and the treatment group alone, all of the correlations were weak and statistically nonsignificant (r = −0.11 to 0.03; all P values > .10).
Finally, because at baseline and at each follow-up visit all participants received information regarding a healthy lifestyle, which is not a routine component of periodontal therapy, we examined the effects of weight loss on the periodontal outcomes. Overall, mean (SD) changes from baseline in BMI were nominal and did not differ significantly between groups (treatment group = −0.10 
DISCUSSION
We used data from a randomized controlled trial to study predictors of the response to nonsurgical periodontal therapy in patients with T2DM and moderate to advanced periodontitis. As expected, treatment (versus no treatment) was associated with the largest average change in all clinical measures. Baseline disease severity was the only other variable consistently associated with changes in these measures. Obesity (BMI > 30) was associated with a small but more favorable response in terms of change in PD and BOP, but not in CAL. We also found that Hispanic participants responded more favorably than did non-Hispanic participants to treatment in terms of PD and CAL changes.
Interestingly, baseline glycemic control (measured as HbA 1c level), duration of diabetes, and smoking were not associated significantly with treatment response. In other words, participants with long-standing diabetes or higher baseline HbA 1c values did not respond less favorably than did those with more recent diabetes diagnoses or better glycemic control. This finding contradicts a commonly held notion that hyperglycemia, through its effects on immune functions and the microvasculature, 16 adversely affects a person's response to periodontal treatment. For example, Santos and colleagues 17 treated a small number of people who had diabetes with scaling and root planing and maintenance care and found that participants with baseline HbA 1c values ranging from 4.8 to 8.7 percent had significantly greater gains in CAL than did those with baseline values between 9 and 12 percent. The absolute difference between groups in the Santos and colleagues study, however, was slight, and the groups did not differ in terms of PD and BOP changes after receiving treatment. The lack of a similar CAL finding in our study may be because DPTT enrolled participants whose HbA 1c values were within a relatively narrow range (≥ 7 percent and < 9 percent).
Smoking also was not associated with change in any clinical response measure. The deleterious effects of cigarette smoking on periodontal treatment response are well established in the general population, 18 although we are not aware of any study in which researchers examined smoking's effects exclusively in people with T2DM. Less than 13 percent of participants in DPTT were current smokers, which limited the power of our sample to help detect differences in responses between smokers and nonsmokers. Nonetheless, we found no evidence to suggest that the treatment response was associated with smoking status (current, former or never). Although we did not show results for the bivariate analyses, P values used to compare change in the clinical measurements among smoking groups all were greater than . 30 .
When one considers this study's findings, it is important to consider the magnitude of the clinical response. Investigators in periodontal treatment studies often report PD changes stratified either according to baseline PD or at qualifying teeth or sites only. The full-mouth mean reduction in PD after scaling and root planing in the present our study was 0.47 mm, which included initially healthy and diseased sites. Haffajee and colleagues 19 reported similar mean full-mouth PD reductions six months after scaling and root planing alone or with adjunctive antibiotics. Findings in other studies of patients with chronic periodontitis 20-22 indicated that whereas those patients had greater full-mouth mean PD reductions (0.6-1.0 mm) than did the participants in our study, they also had higher initial mean PDs (3.6-4.4 mm) than did our participants (3.3 mm) ( Table 1) . When stratified according to baseline PD, changes in PD and CAL after treatment in DPTT participants were similar to those described by others. For example, in pockets initially 4 to 6 mm in depth, Cobb 1 reported † Based on the final regression with treatment group, body mass index, baseline BOP, clinical site (data not shown) and interaction between treatment and baseline BOP (data not shown) as covariates. Age, race, Hispanic ethnicity, diastolic blood pressure, self-reported overall health, gingival health and frequency of flossing also were evaluated but were removed from the final model because they were not associated significantly with six-month BOP change. The plaque score was excluded from the final model because it was associated collinearly with baseline BOP. ‡ CI: Confidence interval. § P value remained significant after Bonferroni adjustment (P < 05/15 = .003). 25 and without 19 diabetes have shown percentage point reductions similar to ours. Nonetheless, the apparent disassociation between changes in PD, CAL and BOP in our study is difficult to reconcile. The relatively modest reductions may be attributed to the fact that all participants had T2DM, which itself is associated with increased gingival bleeding 26 or may be a consequence of widespread aspirin use among study participants. Regular aspirin use has been associated with increased gingival bleeding. 27, 28 About 50 percent of DPTT participants were taking aspirin (up to 325 mg) on a daily basis at baseline; the amount increased to 56 percent at the six-month examination. The theory that prevalent aspirin use in DPTT participants may have contributed to residual bleeding, however, is speculative. We did not include aspirin use, or change in aspirin use, in our prediction models. Investigators in other intervention studies in people with T2DM reported greater BOP reductions after treatment than we observed, although the prevalence of aspirin use was not reported in these trials. 17, [29] [30] [31] Residual BOP in our treatment participants also may be attributed to levels of residual detectable plaque in participants. 15 Despite the provision of repeated oral hygiene instructions, most tooth surfaces in treatment participants had detectable (not necessarily visible) plaque at the six-month visit. The omission of plaque scores from the final statistical models, however, does not mitigate the importance of plaque control in periodontal treatment, but rather was based on its collinear relationship with baseline disease severity measures-that is, baseline plaque scores and disease severity scores were similarly associated with changes in the disease measures, and we included only the baseline disease severity measures in the final models.
We found that participants who were obese experienced slightly but significantly greater reductions in PD and BOP than those among people who were not obese, which is in contrast to recent findings in people without diabetes. For example, Suvan and colleagues 32 reported that increasing BMI and obesity were associated with smaller short-term reductions in PD after scaling and root planing. Obesity was not associated significantly with changes in bleeding, and only 21 percent of their sample was obese. Previous studies regarding the association between obesity and periodontitis have yielded inconsistent results, highlighting the need for additional intervention trials to increase our understanding of the role of obesity in defining the risk of experiencing periodontitis and periodontal treatment responses. 33 In our study, all participants had T2DM, and 72 percent were obese (BMI > 30 kg/m 2 ). Only a small number of participants (N = 20) were of normal weight (BMI < 25), which precluded us from exploring associations with treatment response across all BMI categories (that is, underweight, normal, overweight, obese). In terms of BMI measures, however, our sample appears highly representative of U.S. adults with T2DM. In 2005 and 2006, 62.4 percent of U.S. adults with T2DM were obese, 34 and this proportion continues to increase steadily over time. In this same national report, the mean BMI was 34.2 kg/m 2 , which is nearly identical to the mean for DPTT participants. 15 In terms of the relationship between obesity and periodontal treatment response, however, our findings likely are not generalizable to patients who do not have T2DM, most of whom are not obese.
Our study has several limitations. DPTT's enrollment criteria may limit the generalizability of our findings, even among those with T2DM. For example, participants were required to have moderate to poorly controlled T2DM and moderate to advanced periodontitis; fewer than one in three screened people with diabetes were eligible for the trial. 15 Thus, our findings may not apply to people with HbA 1c values outside the study range or with less severe or extensive periodontitis. We also evaluated only the short-term (six-month) response to therapy. Factors such as smoking and baseline HbA 1c level may be important predictors of longer-term outcomes, such as clinical changes over 12 or more months. Finally, although participants responded well to therapy in terms of PD and CAL changes, overall the changes in BOP were modest. A different set of characteristics may have been associated with change in BOP had these changes been more pronounced.
Finally, a significant clinical-center effect on treatment response remained after adjustment for race, ethnicity and baseline disease severity, all of which differed significantly among the centers. The source of participants also varied among centers (results not shown), with some centers recruiting a greater proportion of participants from diabetes clinics or dental clinics or by means of study advertisements. We know of no biological reasons why the periodontal treatment response should vary according to recruitment source, and we did not include this variable in the models. In sum, we could not account for the clinical-center effect, which may have been caused by center differences in unmeasured confounding variables or examiner and therapist practices. Rather than ignore this effect, however, we included clinical center in the model but did not report it, for the reasons stated earlier.
Despite these limitations, the study has several strengths. To our knowledge, DPTT is the largest periodontal intervention trial of people with T2DM to date. The sample population was diverse in terms of race, ethnicity and geographic location. 15 Finally, although we analyzed the data on a per-protocol basis (that is, included participants had complete baseline and six-month data), the loss-to-follow-up rate in the parent study was low (about 7 percent). Thus, participants included in this study were representative of the larger trial sample.
CONCLUSIONS
This study demonstrated that baseline disease severity is associated with the magnitude of clinical response after nonsurgical therapy in people with T2DM. Obesity and Hispanic ethnicity also may be useful indicators of responsiveness. To the best of our knowledge, this is the first study in which investigators have assessed prognostic factors for response to periodontal therapy in patients with T2DM. Thus, these findings need to be corroborated by others before this information is incorporated into the treatment planning processes or prognostic assessments for this population. ■
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